Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CER-001 Atherosclerosis Regression ACS Trial; A Phase II Multi-Center, Double-Blind, Placebo-Controlled, Dose-Focusing Trial Of Cer-001 In Subjects With Acute Coronary Syndrome

Next Previous
Search
Trial Profile

CER-001 Atherosclerosis Regression ACS Trial; A Phase II Multi-Center, Double-Blind, Placebo-Controlled, Dose-Focusing Trial Of Cer-001 In Subjects With Acute Coronary Syndrome

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CER 001 (Primary)
  • Indications Acute coronary syndromes
  • Focus Therapeutic Use
  • Acronyms CARAT
  • Sponsors ABIONYX Pharma; Cerenis Therapeutics

    • Most Recent Events

    • 30 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 19 Jan 2017 This trial has been completed in Hungary (end date: 30 Nov 2016).
    • 08 Nov 2016 According to Cerenis Therapeutics media release, Prof. Stephen Nicholls is the principal investigator of this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top